NASDAQ:NMAD Lixte Biotechnology (NMAD) Stock Price, News & Analysis $3.82 -0.04 (-1.04%) As of 11:08 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Lixte Biotechnology Stock (NASDAQ:NMAD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lixte Biotechnology alerts:Sign Up Key Stats Today's Range$3.77▼$3.9550-Day Range$3.65▼$7.6752-Week Range$2.36▼$8.38Volume18,721 shsAverage Volume197,029 shsMarket Capitalization$61.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles. Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms. These candidates are currently advancing through early-phase clinical trials in solid tumors, where Lixte is evaluating safety, tolerability and preliminary measures of anti-tumor activity. Research and development activities are conducted in collaboration with academic institutions and contract research organizations to leverage cutting-edge science and streamline the path to clinic. Headquartered in the United States, Lixte Biotechnology maintains its R&D operations in California and works with strategic partners to extend its global reach. The company’s leadership team comprises seasoned executives and scientists with extensive experience in oncology drug development, regulatory affairs and commercial strategy. Through disciplined pipeline management and targeted clinical development, Lixte aims to deliver differentiated therapies that address significant unmet needs in cancer care. AI Generated. May Contain Errors. Read More Lixte Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreNMAD MarketRank™: Lixte Biotechnology scored higher than 8% of companies evaluated by MarketBeat, and ranked 631st out of 656 stocks in the industrials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingLixte Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLixte Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Lixte Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lixte Biotechnology is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lixte Biotechnology is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLixte Biotechnology has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.48% of the float of Lixte Biotechnology has been sold short.Short Interest Ratio / Days to CoverLixte Biotechnology has a short interest ratio ("days to cover") of 2.82, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lixte Biotechnology has recently increased by 0.45%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLixte Biotechnology does not currently pay a dividend.Dividend GrowthLixte Biotechnology does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.94 News SentimentLixte Biotechnology has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Industrials companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lixte Biotechnology this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for NMAD on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders7.30% of the stock of Lixte Biotechnology is held by insiders.Percentage Held by Institutions5.10% of the stock of Lixte Biotechnology is held by institutions.Read more about Lixte Biotechnology's insider trading history. Receive NMAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NMAD Stock News HeadlinesNOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERSSeptember 4, 2026 | globenewswire.comNOMAD Power Solutions, Inc. Receives DOE Authorization to Advance Vermont Long-Duration Energy Storage Project into Phase 3August 26, 2026 | globenewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 9 at 1:00 AM | Base Camp Trading (Ad)NOMAD Achieves UL 9540 Certification for 1 MW Transportable Battery Energy Storage SystemAugust 19, 2026 | globenewswire.comNOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATEAugust 14, 2026 | finance.yahoo.comAI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMADJuly 6, 2026 | prnewswire.comLIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMADJuly 6, 2026 | globenewswire.comLIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMSJuly 2, 2026 | globenewswire.comSee More Headlines NMAD Stock Analysis - Frequently Asked Questions How have NMAD shares performed this year? Lixte Biotechnology's stock was trading at $3.93 at the start of the year. Since then, NMAD stock has decreased by 1.8% and is now trading at $3.86. How were Lixte Biotechnology's earnings last quarter? Lixte Biotechnology Holdings, Inc. (NASDAQ:NMAD) posted its quarterly earnings data on Wednesday, November, 12th. The company reported ($0.33) EPS for the quarter. When did Lixte Biotechnology's stock split? Lixte Biotechnology's stock reverse split before market open on Monday, June 5th 2023.The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Lixte Biotechnology's major shareholders? Top institutional investors of Lixte Biotechnology include Legacy Wealth Managment LLC ID (3.73%), BlackRock Inc. (0.51%), FNY Investment Advisers LLC (0.30%) and Equitable Holdings Inc. (0.05%). View institutional ownership trends. How do I buy shares of Lixte Biotechnology? Shares of NMAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lixte Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT). Company Calendar Last Earnings11/12/2025Today9/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 9 days, NMAD's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Electrical Equipment Sub-IndustryElectrical Components & Equipment Current SymbolNASDAQ:NMAD Previous SymbolNASDAQ:LIXT CIK1335105 Webwww.lixte.com Phone(631) 830-7092Fax631-982-5050Employees4Year Founded2006Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.01 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.49% Return on Assets-62.03% Debt Debt-to-Equity RatioN/A Current Ratio12.87 Quick Ratio12.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book3.76Miscellaneous Outstanding Shares16,100,000Free Float14,926,000Market Cap$63.60 million OptionableNot Optionable Beta1.30 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:NMAD) was last updated on 9/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
